Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Kymera Therapeutics (NASDAQ:KYMR) in the last three months. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $44.0, along with a high estimate of $52.00 and a low estimate of $36.00. This upward trend is apparent, with the current average reflecting a 5.19% increase from t…